Please ensure Javascript is enabled for purposes of website accessibility

Why Travere Therapeutics Stock Is Plummeting Today

By Eric Volkman - May 26, 2021 at 1:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA quashes the company's hopes for accelerated approval of a key pipeline drug.

What happened

The stock of Travere Therapeutics (TVTX 1.62%) was on the decline by almost 17% in midafternoon trading Wednesday. That was on the back of dispiriting regulatory news from the rare-disease biotech.

So what

Travere disclosed that the Food and Drug Administration won't grant accelerated approval to its pipeline drug sparsentan as the company had hoped. According to Travere, the regulator said it cannot support such approval based on the company's interim analysis from a recent phase 3 trial of the drug.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

That's a big setback, as sparsentan -- which treats a kidney disorder called focal segmental glomerulosclerosis (FSGS) -- is a leading pipeline drug for Travere. It wanted to formally submit it for accelerated approval in the second half of this year; it no longer expects to do so.

Still, it continues to believe in sparsentan, and is hopeful for its potential. "Based upon our ongoing dialogue with FDA, we believe the [kidney function] data need to further mature to support our New Drug Application for accelerated approval in this indication," the company quoted CEO Eric Dube as saying.

He added that he and his team "still have a potential opportunity to pursue a path to an accelerated approval submission in the U.S. next year."

Now what

The immediate prospects for sparsentan might be brighter in the European Union, where Travere says it has "received administrative support" for getting conditional marketing authorization for the drug. As with its previous U.S. ambitions, the biotech wants to put sparsentan on the market in the second half of 2021.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Travere Therapeutics, Inc. Stock Quote
Travere Therapeutics, Inc.
$27.59 (1.62%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.